logo print

Focus on HER1/EGFR in cancer: Summary

Slide Deck

View the HER1/EGFR slide deck

Slide Deck

HER1/EGFR signaling is frequently dysregulated in cancer

  • HER1/EGFR signaling may be dysregulated through receptor overexpression, mutation, or both3-5
  • Dysregulated HER1/EGFR signaling has multiple cellular effects, including1,3
    • Increased cell cycle progression
    • Tumor cell survival and proliferation
    • Increased transcription of genes
    • Cell migration and metastasis

HER1/EGFR is a negative prognostic factor

  • In NSCLC, HER1/EGFR has been linked to shorter overall survival12
    • Additional clinical research indicates that HER1/EGFR phosphorylation, rather than receptor overexpression, affects prognosis10
  • In pancreatic cancer, HER1/EGFR has been correlated with
    • Higher tumor grade13
    • More advanced disease14
    • Shorter overall survival14

HER1/EGFR represents a potential therapeutic target

  • Methods of targeting could include
    • Targeting HER1/EGFR-specific ligands
    • Targeting the ligand-binding domain of HER1/EGFR
    • Targeting the tyrosine kinase domain of the receptor
    • Targeting downstream signaling pathways

Additional clinical research is needed to better clarify the role of HER1/EGFR in cancer.

 

Next Section: HER1: ReferencesArrow

ReferencesArrow